Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery

被引:1
|
作者
Vanderzwaag, Baeleigh [1 ,2 ]
Garcia-Romeu, Albert [3 ,4 ]
Garcia-Barrera, Mauricio A. [1 ,2 ]
机构
[1] Univ Victoria, Dept Psychol, 3800 Finnerty Rd, Victoria, BC V8P 5C2, Canada
[2] Inst Aging & Lifelong Hlth, Victoria, BC, Canada
[3] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA
[4] Ctr Psychedel & Consciousness Res, Baltimore, MD USA
基金
加拿大自然科学与工程研究理事会;
关键词
athletes; mTBI; psilocybin; psychedelics; sports concussion;
D O I
10.1177/20451253241264812
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of the most widely studied classic psychedelics which has shown good safety and clinical benefit for major depression and substance use disorders. Athletes frequently sustain concussions and often experience myriad symptoms, including cognitive and mood issues, which can persist for weeks or months in 10%-30% of athletes. Psilocybin may be a potential symptom management option for athletes with persisting concussion symptoms.Objectives: This study sought to summarize athlete psychedelic use, among other substances, and to examine the willingness of the sports community to engage in or support psilocybin-assisted therapy (PAT) for concussion recovery and management of persisting concussion symptoms.Methods: In total, 175 (n = 85 athletes; n = 90 staff) respondents completed an online survey distributed in Canada and the United States which queried sport involvement and demographics, substance use, concussion history, and knowledge and willingness about psilocybin. The reporting of this study conforms to the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) statement.Design: Substance use rates were summarized across athletes and team staff members and a path analysis was used for each sample to identify predictors of willingness to use PAT (athletes) or support PAT (staff) for concussion recovery. Participants were also asked to identify perceived barriers to the implementation of PAT for sports-related concussions, and to indicate their overall willingness.Results: Psychedelics were the third most used substance in the past year among athletes (35.8%) while regular psychedelic use was quite low in athletes (7.5%). A path analysis conducted in RStudio found that attitudes toward psilocybin and knowledge of psilocybin were significant predictors for both athletes and staff members of their willingness to use or support PAT for concussion recovery. Athletes reported likely engaging in PAT (61.2%) and staff (71.1%) reported that they would support their athletes using PAT.Conclusion: The results of this study suggest that the sports community may be receptive to PAT and athletes would be willing to engage in it for concussion recovery and/or the management of persisting post-concussion symptoms (PPCS). Future research should examine the effects of psilocybin for PPCS to inform whether there is any impact while addressing concerns regarding long-term effects of psilocybin use. Psilocybin-assisted therapy for concussion recoveryStudy purpose: Psychedelics such as psilocybin have been studied largely in patients with terminal cancers, but research has begun expanding to the mental health field and for cognitive benefit. Athletes who sustain concussions and experience persisting concussion symptoms are at an increased risk of developing symptoms of anxiety and depression and dealing with cognitive symptoms such as impaired memory, attention, and concentration. Current research with psilocybin suggests that examining the use of psilocybin in athletes post-concussion for the management of mood and cognitive symptoms is a worthwhile endeavour. However, it is unclear whether the sports community is receptive to this line of research.What did the researchers do? We employed a survey study to athletes and sports staff across Canada and the United States to examine current psychedelic use, motivations for use, and willingness to use or support psychedelic-assisted therapy (PAT) in athletes post-concussion.What did the researchers find? 175 respondents completed an online survey distributed in Canada and the United States (n = 85 athletes; n = 90 staff). Psychedelics were the third most used substance in the past year among athletes (35.8%) while regular psychedelic use was quite low in athletes (7.5%). A path analysis conducted found that attitudes towards psilocybin and knowledge of psilocybin were significant predictors for both athletes and staff members of their willingness to use or support PAT for concussion recovery. Athletes reported likely engaging in PAT (61.2%) and staff (71.1%) reported that they would support their athletes using PAT.What do these findings mean? Our study suggests that athletes may be willing to use PAT if they had sustained a concussion and were dealing with persisting symptoms while their coaches and other staff members would also be willing to support them. Thus, further research through randomized clinical trials will be necessary to understand the effects of psilocybin and other psychedelics on persisting concussion symptoms in athletes.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment
    Meir, Priel
    Taylor, Leslie
    Soares, Jair C.
    Meyer, Thomas D.
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 323 : 748 - 754
  • [32] A case-study evaluation of the "Copenhagen Music Program" for psilocybin-assisted therapy
    Ratkovic, Gina
    Sosteric, Mike
    Sosteric, Tristan
    FRONTIERS IN PSYCHOLOGY, 2023, 14
  • [33] Palliative care patients' attitudes and openness towards psilocybin-assisted psychotherapy for existential distress
    Wang, Julia Ruixi
    Mendez Araque, Samuel J.
    Micciche, Gina
    Mcmillan, Andrew
    Coughlin, Emily
    Mattiola, Rosalie
    English, Diana
    Kaliebe, Kristopher
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [34] Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy
    O'Donnell, Kelley C.
    Anderson, Brian T.
    Barrett, Frederick S.
    Bogenschutz, Michael P.
    Grob, Charles S.
    Hendricks, Peter S.
    Kelmendi, Benjamin
    Nayak, Sandeep M.
    Nicholas, Christopher R.
    Paleos, Casey A.
    Stauffer, Christopher S.
    Gukasyan, Natalie
    AMERICAN JOURNAL OF PSYCHIATRY, 2024, 181 (01): : 74 - 75
  • [35] Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder
    Agrawal, Manish
    Richards, William
    Beaussant, Yvan
    Shnayder, Sarah
    Ameli, Rezvan
    Roddy, Kimberly
    Stevens, Norma
    Richards, Brian
    Schor, Nick
    Honstein, Heather
    Jenkins, Betsy
    Bates, Mark
    Thambi, Paul
    CANCER, 2024, 130 (07) : 1137 - 1146
  • [36] Psilocybin-Assisted Group Therapy for Demoralization in Long-Term AIDS Survivors
    Anderson, Brian
    Danforth, Alicia
    Daroff, Robert
    Stauffer, Christopher
    Dilley, James
    Mitchell, Jennifer
    Woolley, Joshua
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S182 - S182
  • [37] PSILOCYBIN-ASSISTED THERAPY FOR MENTAL HEALTH: HOW DO WE ADVANCE THE FIELD?
    Meikle, S.
    Liknaitzky, P.
    Rossell, S.
    Ross, M.
    Strauss, N.
    Thomas, N.
    Murray, G.
    Williams, M.
    Castle, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (1_SUPPL): : 63 - 64
  • [38] Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial
    Davis, Alan K.
    Barrett, Frederick S.
    May, Darrick G.
    Cosimano, Mary P.
    Sepeda, Nathan D.
    Johnson, Matthew W.
    Finan, Patrick H.
    Griffiths, Roland R.
    JAMA PSYCHIATRY, 2021, 78 (05) : 481 - 489
  • [39] Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
    Plourde, Louis
    Chang, Sue-Ling
    Farzin, Houman
    Stephan, Jean-Francois
    Fallu, Jean-Sebastien
    Dorval, Michel
    JOURNAL OF PSYCHEDELIC STUDIES, 2025,
  • [40] Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience
    Stauffer, Christopher S.
    Anderson, Brian T.
    Ortigo, Kile M.
    Woolley, Joshua
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2021, 4 (02) : 526 - 532